tetano
Editor, Senior Moderator
Genomics
. 2021 Jan 19;S0888-7543(21)00025-2.
doi: 10.1016/j.ygeno.2020.12.041. Online ahead of print.
Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID19 therapy
Henry Sung-Ching Wong[SUP] 1 [/SUP], Chin-Lin Guo[SUP] 2 [/SUP], Gan-Hong Lin[SUP] 3 [/SUP], Kang-Yun Lee[SUP] 4 [/SUP], Yukinori Okada[SUP] 5 [/SUP], Wei-Chiao Chang[SUP] 6 [/SUP]
Affiliations
Abstract
The recent outbreak of coronavirus disease 2019 (COVID-19) by SARS-CoV-2 has led to uptodate 24.3 M cases and 0.8 M deaths. It is thus in urgent need to rationalize potential therapeutic targets against the progression of diseases. An effective, feasible way is to use the pre-existing ΔORF6 mutant of SARS-CoV as a surrogate for SARS-CoV-2, since both lack the moiety responsible for interferon antagonistic effects. By analyzing temporal profiles of upregulated genes in ΔORF6-infected Calu-3 cells, we prioritized 55 genes and 238 ligands to reposition currently available medications for COVID-19 therapy. Eight of them are already in clinical trials. Of particular importance is the emergence of immune checkpoint inhibitors targeting PD-L1 that have not been used in COVID-19 treatment. We also pinpointed 16 drug groups from the Anatomical Therapeutic Chemical classification system, with the potential to mitigate symptoms of SARS-CoV-2 infection and thus to be repositioned for COVID-19 therapy.
Keywords: COVID-19; Drug repositioning; SARS-CoV-2; Transcriptomic and network analysis.
. 2021 Jan 19;S0888-7543(21)00025-2.
doi: 10.1016/j.ygeno.2020.12.041. Online ahead of print.
Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID19 therapy
Henry Sung-Ching Wong[SUP] 1 [/SUP], Chin-Lin Guo[SUP] 2 [/SUP], Gan-Hong Lin[SUP] 3 [/SUP], Kang-Yun Lee[SUP] 4 [/SUP], Yukinori Okada[SUP] 5 [/SUP], Wei-Chiao Chang[SUP] 6 [/SUP]
Affiliations
- PMID: 33482326
- DOI: 10.1016/j.ygeno.2020.12.041
Abstract
The recent outbreak of coronavirus disease 2019 (COVID-19) by SARS-CoV-2 has led to uptodate 24.3 M cases and 0.8 M deaths. It is thus in urgent need to rationalize potential therapeutic targets against the progression of diseases. An effective, feasible way is to use the pre-existing ΔORF6 mutant of SARS-CoV as a surrogate for SARS-CoV-2, since both lack the moiety responsible for interferon antagonistic effects. By analyzing temporal profiles of upregulated genes in ΔORF6-infected Calu-3 cells, we prioritized 55 genes and 238 ligands to reposition currently available medications for COVID-19 therapy. Eight of them are already in clinical trials. Of particular importance is the emergence of immune checkpoint inhibitors targeting PD-L1 that have not been used in COVID-19 treatment. We also pinpointed 16 drug groups from the Anatomical Therapeutic Chemical classification system, with the potential to mitigate symptoms of SARS-CoV-2 infection and thus to be repositioned for COVID-19 therapy.
Keywords: COVID-19; Drug repositioning; SARS-CoV-2; Transcriptomic and network analysis.